The Burden of Illness for Metastatic Synovial Sarcoma (MSS) and Myxoid Round Cell Liposarcoma (MMRCLS): A Seer-Medicare Analysis
Author(s)
Wang H1, Purser M2, Happ LP1, St. Laurent S3, Kobayashi M4, Pokras S5
1GSK, Collegeville, PA, USA, 2GSK, Apex, NC, USA, 3GSK, Cambridge, MA, USA, 4GlaxoSmithKline, Durham, NC, USA, 5GlaxoSmithKline, Bryn mawr, PA, USA
Presentation Documents
OBJECTIVES:
This study aimed to describe treatment patterns, healthcare resource utilization (HCRU), and associated costs and outcomes in patients with mSS/mMRCLS, which has not been previously studied.METHODS:
Eligible patients in SEER-Medicare dataset (2007-2015) had mSS/mMRCLS diagnosis, aged ≥65y at metastatic diagnosis (index date), ≥6-months of Medicare Part A & B coverage pre-index and ≥1-month of follow-up post-index. Treatment patterns, median overall survival (mOS), cancer-related and all-cause HCRU/costs were summarized overall and by line of therapy (LOT). Specific systemic therapies were captured across outpatient and pharmacy settings, but not from inpatient setting.RESULTS:
Among the included 121 patients (median age at index, 75 years; median follow-up, 12 months), 39 received ≥1 LOT of systemic therapies, and 19 proceeded with 2L+ treatments. The most common regimens were doxorubicin-based in the 1L (41%) and docetaxel-gemcitabine combination in the 2L (32%). The mOS (95%CI) from 1L and 2L initiation was 14.92 (6.57-20.87) and 11.95 (6.34-14.14) months, respectively. Among all patients, 85% and 70% had ≥1 cancer-related outpatient visits and hospitalizations, respectively. The median (Q1-Q3) number of cancer-related hospitalizations within 1L and 2L+ was 1 (1-2) and 2 (1-4), respectively; and the median duration per stay was 7 (5-13) days and 10 (5-23) days, respectively. Cancer-related total costs represented >65% of all-cause total costs, with ~20% of cancer-related total costs for systemic therapies. The median (Q1-Q3) total cost of cancer-related care per-patient-per-month in 1L and 2L+ was $5,987 ($3,575-$10,832) and $6,051 ($3,344-$10,406), respectively. The largest cost drivers included physician (1L 35%; 2L+ 34%), outpatient (1L 26%; 2L+ 27%) and inpatient services (1L 27%; 2L+ 18%).CONCLUSIONS:
This study showed substantial HCRU and direct medical cost associated with mSS/mMRCLS in elderly. Most patients did not receive systemic treatments and the prognosis remained poor. This study emphasizes the need for effective treatments for mSS/mMRCLS.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EE448
Topic
Economic Evaluation
Topic Subcategory
Trial-Based Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas